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SOMETHING MUST BE DONE: AN ARGUMENT FOR THE
PARTIAL DEREGULATION OF RESEARCH ON BIPOLAR
DISORDER AND THE IMPLEMENTATION OF ROLLING
INFORMED CONSENT
JanaLee S. Kraschnewski*
Bipolar disorder (BD) cripples the lives of countless individuals across the globe.
The healthcare community has had difficulty securing effective, long-term treat-
ment for this disease. This Note argues that enlarging the pool of possible research
subjects through partial deregulation of BD research would facilitate the develop-
ment of better treatment. This Note further proposes the implementation of a system
of rolling informed consent to ensure that actual and full consent is obtained from
BD research subjects.
Retaining his original sensibility.., he gives himself up to all the ex-
travagances of maniacal fury, or sinks inexpressibly miserable into the
lowest depths of despondence and melancholy. If the forme, he resem-
bles in ferocity the t[i]ger and meditates destruction and revenge. If
the latter, he withdraws from society, shuns the plots and inveigle-
ments which he imagines to surround him, and fancies himself an
object of human persecution and treachery, or a victim of divine
vengeance and reprobation.
-Philippe Pinel, A Treatise on Insanity (1806)'
Winston Churchill. Ernest Hemingway. Abraham Lincoln.
Virginia Woolf. Former Chicago Bears first-round draft pick Alonzo
Spellman. "Terminator" star Linda Hamilton. These prominent
individuals, all considered great successes in their respective fields,
had/have one thing in common: they all expressed symptoms of
bipolar disorder ("BD").2 In fact, BD has been recognized as a
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sity of Michigan Law School. Thank you to Professor Joseph Vining, Rebecca Zissel, Tom
Hitchcock, Jay Surdukowski, and Dr. Carey Cuprisin. Special thanks to Idelle, Melvin, and
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I. PHILIPPE PINEL, A TREATISE ON INSANITY (1806), quoted in RoY PORTER, THE FA-
BER BOOK OF MADNESS 12-13 (1991).
2. Parris M. Kidd, Bipolar Disorder as Cell Membrane Dysfunction: Progress Toward Integra-
tive Management, 9 ALTERNATIVE MED. REV. 107 (2004); David Haugh, Bipolar ex-Bear Hoping.
Former Defensive Tackle Alonzo Spellman Wants to Make NLF Comeback, CHI. TRiB., Jan. 25, 2005,
at Cl; Interview by Larry King with Linda Hamilton, Actress, on Larry King Live (CNN televi-
sion broadcast Oct. 14, 2005).
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mental disorder for thousands of years! In all that time, though,
humankind has been unable to conquer the illness that has been
(and continues to be) mentally crippling to millions of people
worldwide.4
Something must be done to help those afflicted with this disease
that tears apart lives. The medical community has made little sig-
nificant progress in the search for treatment for this disease since
the discovery of lithium as a mood stabilizer over thirty years ago.
Current federal regulations inhibit the progress.
6
The time has come for the partial deregulation of federally-
funded research seeking to find a new treatment for BD in adults.
Because of the unique nature of BD, it should not be subject to the
current Code of Federal Regulations (C.F.R.), but rather to a separate
set of appropriately tailored rules. Because it is no coincidence that
a disproportionately large number of incarcerated individuals ex-
perience bipolar symptoms, this Note argues that research should
be allowed on prisoners provided that appropriate informed con-
sent is given. The Note further argues that, because of the varying
mental states a bipolar patient can endure, informed consent from
such research subjects should be obtained on a rolling basis.
To begin, this Note examines some basic facts and figures of BD,
including a synopsis of current treatment options. Then it explores
why the disease is such a problem in American society, and why
something must be done to facilitate successful research. Next, it
analyzes current experimentation and the role that the Declaration
of Helsinki and the C.F.R. play. Once this foundation is established,
the Note proposes two reforms to the current legal treatment of
bipolar research: (1) § 46.301 of the C.F.R. should not apply to bi-
polar research, thereby allowing prisoners to participate in
experimental studies pertaining to the disease; and (2) there
should be implementation of a series of rolling consent confirma-
tions for bipolar subjects to ensure that consent is truly and freely
given.
3. BD has been recognized since the time of Hippocrates in 400 B.C. Kidd, supra
note 2, at 107.
4. Some experts estimate that 1.3% to 1.6% of the general population will experience
BD in a lifetime. Bruno Mfiller-Oerlinghausen et al., Bipolar Disorder, 359 THE LANCET 241
(2002). Others estimate that the percentage is as high as 3.7%. Kidd, supra note 2, at 108.
5. See, e.g., Joseph F. Goldberg & Leslie Citrome, Latest Therapies For Bipolar Disorder.
Looking Beyond Lithium., POST GRADUATE MED., Feb. 2005, at 25 ("After more than 50 years
of use in psychiatric medicine, lithium remains the standard against which the potential
mood-stabilizing properties of newer psychotropics are judged.").
6. See, e.g., 45 C.F.R. § 46.306 (2006).
[VOL. 39:3
Something Must Be Done
I. BIPOLAR DISORDER TODAY
In 2000, more than 2.3 million American adults had BD.7 This
disease that "too often erodes the desire and will to live"" results
from abnormalities in brain biochemistry and in circuit structures.9
BD is characterized by extreme mood shifts from intense manic
highs to deep depression. '0 It is associated with a high rate of mor-
bidity as well as mortality."
A. Types of Bipolar Disorder
In all forms of BD, individuals suffer from periods of mania and
depression that can often incapacitate them." The American Psy-
chiatric Association's Diagnostic and Statistical Manual of Mental
Disorders defines manic episodes as including three or more of the
following symptoms: inflated self-esteem or sense of grandiosity,
decreased need for sleep, unusual talkativeness or pressure to keep
talking, racing thoughts, distractibility, and/or excessive involve-
ment in pleasurable activities with a high potential for painful
consequences such as spending sprees, and casual or unsafe sex.13
A major depressive episode lasts at least two weeks and is character-
ized by "either depressed mood or the loss of interest or pleasure
in nearly all activities" and at least four of the following symptoms:
"changes in appetite or weight, sleep, and psychomotor activity;
decreased energy; feelings of worthlessness or guilt; difficultly
thinking, concentrating, or making decisions; or recurrent
thoughts of death or suicidal ideation, plans, or attempts."'4 The
7. NAT'L INST. OF MENTAL HEALTH, DEP'T OF HEALTH & HUMAN SERVS., BIPOLAR
DISORDER RESEARCH AT THE NATIONAL INSTITUTE OF MENTAL HEALTH 1 (2000), available at
http://www.nimh.nih.gov/publicat/bipolarresfact.cfm.




11. Lori Altshuler, Prescribing Antidepressants for Depression in Bipolar Disorder-
Point/Counterpoint, PSYCHIATRIC TIMES, Aug. 2004, at 88.
12. NAT'L INST. OF MENTAL HEALTH, supra note 7, at 1.
13. Am. PSYCHIATRIC ASS'N, DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DIS-
ORDERS 332 (4th ed. 1994); Kathryn Wilkins, Bipolar I Disorder; Social Support and Work, in
HEALTH STATISTICS DIV., STATISTICS CANADA, 2004 ANNUAL REPORT: How HEALTHY ARE
CANADIANS? 21, 23 (2004), available at http://www.statcan.ca/english/freepub/82-003-
SIE/free.htm (click "Annual Report 2004" PDF hyperlink).
14. AM. PSYCHIATRIC ASS'N, supra note 13, at 320.
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average depressive episode experienced by BD individuals lasts six
months. 5 Individuals who have experienced at least one episode of
severe mania are said to have bipolar I disorder. 6 Individuals with
bipolar II disorder have experienced at least one hypomanic epi-
sode. 7 A hypomanic episode differs from a full-blown manic
episode because it is characterized by increased energy, euphoria,
irritability, and intrusiveness to a milder extent than in a manic
episode.' Hypomanic episodes may not prevent a bipolar individ-
ual from participating in everyday life but are noticeable to
others. 9 Cyclothymic disorder is the mildest form of BD and is di-
agnosed in individuals who experience periods of mania and
depression that are not intense enough to meet the criteria for ei-
ther Type I or Type II BD.20
B. Current Treatment Options: Drugs and Psychotherapy
Treatment for BD can vary greatly from patient to patient and
can include medication, therapy, and other treatments. For some
individuals, medication can help and typically includes a combina-
tion of mood-stabilizing medication, anti-mania drugs, and
antidepressants." Lithium and valproate are the most commonly
used mood stabilizing drugs today. Lithium has been approved by
the Food and Drug Administration as a mood-stabilizer since
1970 . Lithium is particularly beneficial for BD patients because it
is proven to reduce suicidal behaviors. Some patients do not re-
spond well to lithium, however, and others cannot tolerate the
drug's side effects. 25 These side effects can include weight gain,
tremor, memory loss, reduced sensitivity to light, and long-term
effects on the kidneys and thyroid. 26 The drug also has other nega-
15. ROGER GRANET & ELIZABETH FERBER, WHY AM I Up, WHY AM I DowN? UNDER-
STANDING BIPOLAR DISORDER 84 (1999).





21. Id. at 6.
22. Id.
23. Goldberg & Citrome, supra note 5, at 30.
24. Id. at 25.
25. NAT'L INST. OF MENTAL HEALTH, supra note 7, at 6.
26. GRANET & FERBER, supra note 15, at 152-53; Goldberg & Citrome, supra note 5, at
25; NAT'L INST. OF MENTAL HEALTH, supra note 7, at 6.
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tive aspects, such as its narrow therapeutic range.2 ' Additionally,
when taken in large amounts, lithium is toxic.2 Divalproex (Depa-
kote) is an anticonvulsant that is often used to treat acute mania.29
The FDA requires labels warning of hyperglycemia and diabetes on
second-generation antipsychotics. °
Treatment via medication often becomes less effective over
time.1 Despite medication and psychotherapy, a high rate of re-
lapse into depression continues in BD patients. 2 Over a period of
five years, 85% of those with BD will have a relapse after one affec-
tive episode. 3  Thus, BD continues to take a high toll on the
individuals who suffer from the disease as well as on society as a
whole. Only 15% of those with BD will consider treatment effective
and describe themselves as being able to function well. 4
II. IMPACT ON THE INDIVIDUAL AND ON SOCIETY
BD often has a crippling effect on the lives of those who suffer
from it. Some patients are incapable of having meaningful emo-
tional relations, holding jobs, and functioning in society.3 5 Some
require hospitalization in periods of intense depression and/or
mania. 6 People with BD are much more likely than the general
population to be obese, afflicted with asthma, suffer from migraine
headaches, and experience panic. They are 4.4 times more likely
than those without BD to have had sexually transmitted diseases
because of hypersexuality that may occur during periods of hypo-
mania or mania. 8
27. Kidd, supra note 2, at 115.
28. Harold Hopkins, Calming the Roller Coaster Ride of Mood Swings, FDA CONSUMER,
Nov. 1988, at 20, 23.
29. Goldberg & Citrome, supra note 5, at 26.
30. Id. at 28.
31. Kidd, supra note 2, at 116.
32. See NAT'L INST. OF MENTAL HEALTH, supra note 7, at 1.
33. Don St. John, Bipolar Affective Disorder: Diagnosis and Current Treatments, 15 CLINI-
CIAN REVS. 6, 44 (2005), available at http://www.clinicianreviews.com/print.asp?page=
courses/105041/lesson.htm.
34. GRANET & FERBER, supra note 15, at 79.
35. See St. John, supra note 33, at 44 ("with two thirds of patients experiencing func-
tional and occupational impairment and strained social relationships").
36. See GRANET & FERBER, supra note 15, at 125.
37. Wilkins, supra note 13, at 24-25.
38. E. FULLER TORREY & MICHAEL B. KNABLE, SURVIVING MANIC DEPRESSION 258
(2002).
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Perhaps the most impacting effect associated with BD is the rela-
tionship between the disease and suicide. According to one study,
BD is the leading cause of suicide in the United States. 9 More than
half of those inflicted with BD have outwardly expressed suicidal
thoughts.40 Twenty-five to 33% of patients with BD attempt sui-
cide. 1 About 15% of all individuals who suffer from the illness will
eventually complete suicide. Accidental death is also frequent,
particularly when a BD patient is experiencing a manic episode,
because "[g] randiosity and delusions may lead the person to drive
100 miles an hour, challenge a police officer holding a gun, or try
to leap between the rooftops of buildings, often with fatal conse-
quences."4 3 The current mortality rate for BD individuals is 2.3
times the mortality rate of the general population.
People with BD are more likely to become involved with sub-
stance abuse, particularly in the United States. 5 Some estimates
indicate that nearly 50% of those with BD have such dependen-
46
cies.
For individuals with BD who are capable of functioning in the
workplace, barriers other than death or injury can keep them out.
The Americans with Disabilities Act of 199047 cast a broad net of
anti-discrimination protections for people with disabilities. 48 For
those with BD, however, the net was not cast wide enough.
The ADA protects many individuals, but courts have been reluc-
tant to use the Act to help those with BD. Many courts accept that
39. GRANET & FERBER, supra note 15, at 2.
40. Ian Daly, Mania, 349 THE LANCET 1157,1158 (1997).
41. St. John, supra note 33, at 43; Mfiller-Oerlinghausen et al., supra note 4, at 241.
42. St. John, supra note 33, at 43.
43. TORREY & KNABLE, supra note 38, at 105.
44. Id. at 104. The mortality rate is much worse in men than in women. The life expec-
tancy of a man with a serious mental illness is 14.1 years shorter than that of a healthy man.
Id. That of a woman with a serious mental illness is reduced by 5.7 years. Id.
45. Msiller-Oerlinghausen et al., supra note 4, at 221.
46. Substance Abuse and Mental Health Servs. Admin.: Hearing Before the Subcomm. on Labor,
Health and Human Servs., 109th Cong. 6 (2005) [hereinafter Hearings] (statement of Charles
C. Curie, Administrator, Substance Abuse and Mental Health Services Administration, U.S.
Dept. of Health and Human Services).
47. Americans With Disabilities Act of 1990, Pub. L. No. 101-336, 104 Stat. 327 (codi-
fied as amended in scattered sections of 42 U.S.C.). Title I of the Act prohibits employment
discrimination and Title II of the Act addresses discrimination in the context of public ser-
vices, programs, and benefits. A disability, for the purposes of these two Titles, means: (1) a
physical or mental impairment that substantially limits one or more of the major life activi-
ties of an individual; (2) a record of such an impairment; or (3) regarded as having such an
impairment. 29 C.F.R. § 1630.2 (2006); 28 C.F.R. § 35.104(4) (2006).
48. Yuri N. Walker, Protecting the Public, The Impact of the Americans with Disabilities Act on
Licensure Considerations Involving Mentally Impaired Medical and Legal Professions, 25 J. LEGAL
MED. 441, 448-49 (2004).
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BD counts as a mental impairment under the ADA, but refuse to
accept that the disease substantially limits a major life activity.
Whether a disease substantially limits a major life activity is deter-
mined on a case-by-case basisY0
Courts that are willing to accept BD as a disability for the pur-
poses of the Act often refuse to extend the Act's protection to
disability-caused misconduct.5' The majority of the circuits believe
that "Congress, in enacting the ADA, intended to prohibit unfair
stereotypes about the disabled but not to shield the disabled from
the consequences of misconduct."5
Because the ADA typically withholds protection from individuals
with BD, otherwise capable individuals are often denied profes-
sional opportunities. This permissible discrimination is prevalent
in several professional fields, but particularly in those of medicine
and law. Though requirements vary state-by-state, many boards of
bar examiners (and boards of medical reviewers) inquire into ap-
plicants' mental history, including BD . The existence of BD is
thought to be related to an applicant's moral character and pre-
sent fitness to practice law or medicine. 4 When applicants
challenge these refusals under the ADA, the state boards' actions
are almost always upheld.55 If there were an effective treatment for
BD, professional review boards might be more willing to consider
BD a non-debilitating condition that does not prevent otherwise
able doctors and lawyers from becoming licensed.
BD also presents a significant drain on fiscal resources. In the
United States, people with serious mental illness represent the
single largest diagnostic group of those receiving Social Security.
56
This is compounded by additional costs by way of foregone
earnings attributable to lower productivity and decreased
49. See, e.g., Taylor v. Phoenixville Sch. Dist., No. 98-1273, 1999 U.S. App. LEXIS 19572,
at *17-18 (3d Cir. Aug. 18, 1999); see also McConnell v. Pioneer Hi-Bred Int'l., Inc., No. CIV.
98-4060-KES, 2000 U.S. Dist. LEXIS 3335 (S.D.S.D. Jan. 25, 2000) (granting summary judg-
ment against an employee who was terminated after twenty-five years of service when
diagnosed with BD that resulted in total or partial disability five months per year).
50. Albertson's, Inc. v. Kirkingburg, 527 U.S. 555, 566 (1999).
51. See, e.g., Valentine v. Standard & Poor's, 50 F. Supp. 2d 262 (S.D.N.Y. 1999); Den
Hartog v. Wasatch Acad., 909 E Supp. 1393 (C.D. Utah 1995).
52. Den Hartog, 909 E Supp. at 1401.
53. Allison Wielobob, Bar Application Mental Health Inquiries: Unwise and Unlawful,
A.B.A. J. HuM. RTs., Winter 1997, at 16, available at http://www.abanet.org/irr/hr/
welobob.html.
54. Applicants v. Tex. State Bd. of Law Exam'rs, No. A93CA740SS, 1994 U.S. Dist.
LEXIS 21290, at *3 (W.D. Tex. Oct. 11, 1994).
55. See, e.g.,Johnson v. Kan. Sup. Ct., 888 F Supp. 1073 (D. Kan. 1995); Tex. State Bd. Of
Law Exam'rs, 1994 U.S. Dist. LEXIS 21290; Walker, supra note 48, at 441,448-49.
56. Hearings, supra note 46, at 6.
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employment.57 In 1991, the cost-of-illness of BD was an estimated
$45 billion. The great cost of this illness on American society is
recognized in the President's 2006 budget proposal for the
Substance Abuse and Mental Health Service Administration.
During the proposal, bipolar patients were referred to in terms of
the "public health burden" they created.6
About 1% of Americans suffer from BD. 61 This figure is compa-
rable to the other populations, such as Ireland,2 but surprisingly
lower than the number of those afflicted in other countries. In
Hungary, for example, three percent of the population has BD and
in Canada, the number is 2.4 percent.63 If the cost to society is so
great in the US, one can only imagine how great it is where BD is
three times as prevalent.
III. REGULATION AND CURRENT EXPERIMENTATION
Current research in the field of BD is inadequate. There is a
greater need for research subjects to combat limited test sample
sizes.
A. Regulation
Human experimentation is governed by international doctrine
as well as by domestic regulation. The Declaration of Helsinki4 and
the Nuremburg Code65 are the two most prominent sources of inter-
national guidelines for research and experimentation involving
humans as subjects. Further research into RD would require re-
search and experimentation on human subjects. The Nuremburg
57. Wilkins, supra note 13, at 22.
58. Mfiller-Oerlinghausen et al., supra note 4, at 241.
59. See Hearings, supra note 46, at 2.
60. Id. at 6.
61. Altshuler, supranote 11, at 88.
62. See Daly, supra note 40, at 1157.
63. Wilkins, supra note 13, at 23.
64. WORLD MED. ASS'N, WORLD MED. ASS'N DECLARATION OF HELSINKI: ETHICAL
PRINCIPLES FOR MEDICAL RESEARCH INVOLVING HUMAN SUBJECTS (1964), available at
http://www.wma.net/e/policy/pdf/17c.pdf [hereinafter Helsinki Declaration].
65. THE NUREMBERG CODE, in 2 TRIALS OF THE WAR CRIMINALS BEFORE THE NUREM-
BERG MILITARY TRIBUNALS UNDER CONTROL COUNCIL LAW No. 10, 181-82 (Government
Printing Office, 1949), available at http://www.hhs.gov/ohrp/references/nurcode.htm.
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Code, developed after the trials of Nazi doctors at Nuremburg after
World War II, states that voluntary consent of human subjects is
absolutely essential. 66 It also requires that experimentation avoid all
unnecessary physical and mental suffering and injury to the sub-
jects, and that the risk involved in the experiment never exceeds its
67humanitarian importance.
The Declaration of Helsinki was promulgated by the World Medi-
cal Association, of which the United States is a member.68 The
introduction to the Declaration quotes the International Code of Medi-
cal Ethics and declares the norm applicable to all medicine,
experimental or otherwise: "A physician shall act only in the pa-
tient's interest when providing medical care which might have the
effect of weakening the physical and mental condition of the pa-
tient. 69 The Declaration espouses various principles, like respecting
the privacy of the subject,
70 evaluation of costs/risks and benefits,
71
and the right of test subjects to abstain from participation or to
withdraw consent at any time during the experiment.] It also
leaves much to the discretion of individual member states, like de-
termining what is a "reasonable likelihood that the populations in
which the research is carried out stand to benefit,"03 or "if the im-
portance of the objective outweighs the inherent risks and burdens
to the subject."74 In the United States, these determinations are
made through Institutional Review Boards (IRB) whose roles are
codified in the C.F.R.7
The United States implements essential principles of the Declara-
tion of Helsinki and the Nuremburg Code in the common rule
elements of the C.F.R.76 The common rule applies to all research
involving human subjects conducted, supported or otherwise sub-
ject to regulation by any federal department or agency that takes
66. Id.
67. Id.
68. Helsinki Declaration, supra note 64.
69. Id. at A(3).
70. Id. at B(21).
71. Id. at B(17)-(19).
72. Id. at B(22).
73. Id. at B(19).
74. Id. at B(18).
75. See, e.g., 34 C.F.R. § 97.111 (2006) (describing criteria for Institutional Review
Boards' approval of research); 40 C.F.R. § 26.102(g) (2006) (stating that Institutional Review
Boards must be established for review of human research subject to the Common Rule); 40
C.ER. § 26.109(a) (2006) (stating that Institutional Review Boards are required to review
and have the authority to approve, require modifications in, or disapprove all research ac-
tivities covered by the Common Rule).
76. See generally 40 C.F.R. §§ 26.100-26.111 (2006).
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appropriate administrative action to make the policy applicable to
such research." 40 C.F.R. § 26.111 (a) (1)-(a) (7) list the criteria for
IRB approval of research, which reiterate the basic requirements
under the Declaration of Helsinki (minimized and reasonable risk to
subjects, equitable selection of subjects, informed consent of sub-
jects, protection of the privacy of subjects, and ensuring the safety
of subjects).
B. Current Experimentation
Working within the current C.F.R., researchers have made lim-
ited progress. Presently, experimentation is proceeding on four
main fronts: (1) Pharmacotherapy research, (2) psychiatric treat-
ment, (3) genetic exploration, and (4) alternative possibilities.
1. Pharmacotherapy Research-There is little empirical evidence
about new drugs for BD because there is a lack of double-blind,
placebo-controlled trials that compare the efficacy of different
treatments. 9 Current research in this area has changed from lith-
ium's therapeutic focus to anticonvulsant drugs and second-
generation antipsychotics.8 0 Of the eleven FDA-approved drugs for
BD treatment, the FDA has approved eight of them only within the
past five years.8 ' Despite the recent onslaught of drugs, there has
been limited noticeable impact on the disease. Most drugs are as
effective as lithium but have more tolerable side effects. 2 Many BD
patients take a combination of these drugs to ward off symptoms.
8
Finding an effective combination formula is an experiment unique
to each patient.
77. Id. at § 26,101 (a).
78. Id. at§ 26.111 (a).
79. Altshuler, supra note 11, at 88. The World Medical Association recently clarified
that the Declaration of Helsinki states that placebos should "only be used in the absence of
existing proven therapy ... [or] [w]here for compelling and scientifically sound methodo-
logical reasons its use is necessary ... [or] [w]here a prophylactic, diagnostic or therapeutic
method is being investigated for a minor condition." Helsinki Declaration, supra note 64, at n.1.
80. Goldberg & Citrome, supra note 5, at 25.
81. Chlorpromazine HCI was approved before 1970; lithium was approved in 1970; Di-
valproex sodium was approved in 1995; Olanzapine was approved in 2000; Olanzapine and
fluoxetine HCI capsules as well as Lamotrgine were approved in 2003. Id. at 30-31. In 2004,
the FDA approved Carbamazepine, Risperidone, Quetiapine fumarate, Ziprasidone, and
Ariprazole. Id.
82. Goldberg & Citrome, supra note 5, at 30-31.
83. Id.
[VOL. 39:3
Something Must Be Done
Some pharmacotherapy researchers are seeking agents that acti-
vate gamma-aminobutyric acid (GABA) receptors in the brain.
The effect of the agents is a reduced level of GABA in the cortex,
nucleus accumbens, and brain stem in depressed subjects, yielding
an antidepressant effect.85 Benzodiazepines, such as Alprazolam
(Xanax), increase GABAergic neurotransmission by increasing
GABA reception. 6 Mood stabilizers (lithium) tend to increase
brain GABA Limited data is available about the effects of some
FDA approved drugs on GABA.88 Further research is needed into
the area of GABA to utilize it to its full potential for BD patients.
2. Psychiatric Treatment-Psychiatric treatment is another area
where experimentation is ongoing (but producing few substantial
results). Typical sessions of psychiatric treatment have long been
prescribed for BD patients, but recently the focus has shifted (es-
pecially for young BD patients) to family-based treatment.
8
1
"Engaging parents in the treatment process and reducing the tox-
icity of a negative family environment can contribute to better
treatment engagement, retention, compliance, effectiveness, and
maintenance of gains."90 Family psychiatric treatments can be effec-
tive as an augmentation to other treatments,91 but no
psychotherapy is "of much value unless the person is also taking
medication." 92 Further research must be done to consider precise
methods for administration of such treatment.
Cognitive therapy is another psychiatric frontier. It is similar to
typical psychoanalytic psychotherapy but differs in that cognitive
therapy assumes that the patient's conscious thoughts are important
determinants of behavior (whereas psychoanalytic psychotherapy
focuses on unconscious thoughts) .g This form of therapy has been
used in the past for treatment of depression and anxiety for years,
but only recently has been used to treat BD and is still considered
•94
experimental.
84. Wang & Ketter, The Emerging Role of GABAergic Mechanisms in Mood Disorders,






89. See Guy Diamond & Allan Josephson, Family-Based Treatment Research: A 10-Year Up-
date, 44J. AM. ACAD. OF CHILD & ADOLESCENT PSYCHIATRY 872, 875-76 (2005).
90. Id. at 872.
91. Id. at 873.
92. ToRREY & KNABLE, supra note 38, at 207.
93. Id. at 208.
94. See id. at 209.
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Some patients also experiment with other types of psychiatric
treatment, including Interpersonal and Social Rhythm Therapy
(IPSRT) and Group Therapy.95
3. Genetic Exploration 6--The possibility is great that BD is he-
reditary.97 This possibility leads scientists to believe that BD has a
genetic component, and much research is underway to isolate the
responsible gene or genes.9" One candidate gene is the brain-
derived neutrophic factor (BDNF) gene on chromosome 11. 99
Another possible gene is the variable number tandem repeat
(VNTR) polymorphism in intron 2 of the serotonin transporter
gene (5-HTT).' °° Still other scientists suspect the culprit(s) resides
on chromosomes 18 and/or 21.'
Some researchers who believe that BD is genetic think that ge-
nomic imprinting and mitochondrial inheritance also play a role
in the hereditary nature of BD. °2 Further and more expansive re-
search must be done in this area. By identifying the genes that
make patients susceptible to BD (and the brain proteins these
genes code for), the medical community will be better able to de-
velop more effective treatments, and possibly even preventive
103
measures.
4. Alternative Possibilities-Some BD research today is centered
on treatment that considers alternatives to pharmacotherapy and
gene therapy. One type of alternative research focuses on nutri-
tional supplements, calling upon the healing powers of different
combinations of vitamins, minerals, orthomolecules, herbs, and
95. Id. at 209-11.
96. The reader need not comprehend the scientific details of this section. The author
describes genetic exploration simply to illustrate another frontier to which BD research has
spread.
97. xWette P. Conley et al., Genetic Susceptibility to Psychiatric Disorders, 13 MEDSURG
NURSING 319, 320 (2004) ("Estimates of heritability for BP [Bipolar Disorder] are in the
range of 60%.").
98. See, e.g., NAT'L INST. OF MENTAL HEALTH, supra note 7, at 1 (describing the Na-
tional Institute of Mental Health Bipolar Disorder Genetics Initiative).
99. Conley, supra note 97, at 320. This gene is linked with stress and antidepressant re-
sponses. Id. at 321.
100. Natasha Coyle et al., Variation at the Serotonin Transporter Gene Influences Susceptibility
to Bipolar Affective Puerperal Psychosis, 356 THE LANCET 1490, 1490 (2000) (describing a study
of ninety-seven United Kingdom-born white females with BD who experienced an episode of
severe psychiatric disturbance soon after giving birth). Other possible gene loci include
l8pll, 18q22, 4p16, 21q21, and Xq26. Mfiller-Oerlinghausen et al., supra note 4, at 243.
101. GRANET & FERBER, supra note 15, at 63.
102. Mfiller-Oerlinghausen et al., supra note 4, at 241.
103. NAT'L INST. OF MENTAL HEALTH, supra note 7, at 3.
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omega-3 fatty acids.'" Another area of research postures that infec-
tious agents contribute to BD.'0°
An alternative therapy that has been gaining momentum is elec-
troconvulsive therapy (ECT) and its more subtle sister, transcranial
magnetic stimulation (TMS) .16 ECT has been studied since the
1940s and involves the use of electrical stimulation to generate
generalized tonic-clonic seizures. °7 Despite its negative pubic repu-
tation,08 electroconvulsive therapy has been effective in treating
both depression and mania,'09 but causes amnesia in half of its pa-
tients." This memory loss is usually only temporary."'
TMS was introduced to the scientific community in 1985 "2 and
has been conducted under codified safety regulations since 1993." s
TMS utilizes alternating magnetic fields to induce electrical cur-
rents in the brain."1 It is "a relatively simple, noninvasive, and
usually painless" procedure"5 and, when used repetitively over the
course of two weeks, has been proven to result in significant,
though clinically modest, reductions of depressive symptoms.
For patients who fail to respond to traditional therapy, alternative
therapies can be wonderful, but much more research must be done
to determine what non-pharmaceutical therapies are effective and
104. Kidd, supra note 2, at 107.
105. See Kevin Wack, Deep Pockets Fuel Brain Researchers Quest: A Wealthy Benefactor Allows
Dr. E. Fuller Torrey to Start a Brain Bank and Search for Causes of Schizophrenia, PORTLAND PRESS
HERALD (Maine), Oct. 17, 2004, at A14.
106. Kidd, supra note 2, at 117.
107. Andrew D. Krystal et al., EEG Effects of ECT Implications for rTMS, 12 DEPRESSION &
ANXIETY 157, 157 (2000).
108. GRANET & FERBER, supra note 15, at 5.
109. Hopkins, supra note 28, at 23.
110. Kidd, supra note 2, at 117.
111. GRANET & FERBER, supra note 15, at 179 ("Studies show that the patient's capacity
to retain, learn, and recall new information is undisturbed six to nine months after treat-
ment .").
112. Leon Grunhaus et al., Repetitive Transcranial Magnetic Stimulation Is as Effective as
Electroconvulsive Therapy in the Treatment of Nondelusional Major Depressive Disorder: An Open
Study, 47 BIOLOGICAL PSYCHIATRY 314, 314 (2000).
113. Michael Henry et al., Electromagnetic Stimulation Shows Promise for Treatment-Resistant
Depression, HEALTHYPLACE.COM, http://www.healthyplace.com/Communities/Depression/
treatment/tms/index.asp (last visited Feb. 2, 2006).
114. Kidd, supra note 2, at 117.
115. John Travis, Snap, Crackle, and Feel Good? Magnetic Fields That Map the Brain May Also
Treat Its Disorders, SCIENCE NEWS, Sept. 23, 2000, at 204.
116. Robert M. Berman et al., A Randomized Clinical Trial of Repetitive Transcranial Mag-
netic Stimulation in the Treatment of Major Depression, 47 BIOLOGICAL PSYCHIATRY 332, 332
(2000).
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safe. Private research facilities, funded by private individuals, con-
duct many alternative therapies.117
IV. SUGGESTED REFORMS
A. Permit Experimentation on Volunteering Prisoners
An incredibly prohibitive limitation on the success of bipolar re-
search is the small sample size of participants in studies."8
Increasing the pool of possible subjects would partially alleviate
this problem. One way to increase the pool is to seek possible par-
ticipants among bipolar individuals in state penitentiaries or other
correctional facilities. By relaxing the C.F.R. to allow experimenta-
tion upon consenting bipolar prisoners, the medical community
could make great strides through the use of increased (adequate)
sample sizes. 19
Estimates indicate that 40% of bipolar individuals have been ar-
rested at sometime in their lifetime. ° Upon entering prison,
people with BD remain there about three times longer than pris-
oners who are not mentally ill.' BD rates in prisons are up to five
times greater than in the general population.22 Current figures
estimate that at least one in six prisoners in the United States has a
mental illness.
2 3
The C.F.R. greatly limits the accessibility of inmates to serve as
subjects in medical research experiments. 24 This limitation is due,
117. See, e.g., Wack, supra note 105, at A14 (describing the donation of hundreds of mil-
lions of dollars from a man whose son has BD).
118. See, e.g., Robert L. Findling et al., Double-Blind 18-Month Trial of Lithium Versus Dival-
proex Maintenance Treatment in Pediatric Bipolar Disorder, 44J. AM. ACAD. CHILD & ADOLESCENT
PSYCHIATRY 409, 409--14 (2005).
119. The author would like to stress that only consenting prisoners should be permitted
to participate in experiments. Informed consent requirements should be the same for pris-
oners as for non-incarcerated BD patients. Informed consent from bipolar patients should
be procured on a rolling basis, discussed in detail below.
120. TORREY & KNABLE, supra note 38, at 251.
121. Id.
122. Cynthia L. Blitz et al., Gender-Specific Behavioral Health and Community Release Patterns
Among New Jersey Prison Inmates: Implications for Treatment and Community Reentry, 95 AM. J.
PUB. HEALTH 1741, 1741 (2005); Cynthia Golembeski & Robert Fullilove, Criminal (In)Justice
in the City and Its Associated Health Consequences, 95 AM.J. PUB. HEALTH 1701, 1701 (2005).
123. Golembeski & Fullilove, supra note 122, at 1701. In one Massachusetts prison,
more than 60% of the inmates suffered from some form of mental illness. Peter Reuell,
Mental Illness Rampant Inside Women's Prison, BOSTON HERALD, Aug. 14,2005, News, at 6.
124. See generally 45 C.F.R. § 46.306 (2006).
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in part, to the historical significance that experimentation has
played in prisons.2 5 Correctional facilities offered an ideal test en-
vironment because they harbored stable study groups with many
possible (and often very willing) subjects. 2 6 Prisoners would often
"volunteer" hoping to be rewarded for their bravery.2 7
Naturally, this situation raises ethical concerns. In 1976, all
medical research on federal prisoners was outlawed and research
in state penitentiaries was quick to follow.28 All of the concerns that
lead to this prohibition could be alleviated by treating prisoner
subjects like non-prisoner subjects. Compensation should be equal
and the prisoners should be given no hope of early parole as con-
sideration for participation. Additionally, actual consent must be
validly obtained.
Today, prisoners may usually only participate in research directly
1291related to incarceration. Inmates may participate in medical re-
search not directly related to incarceration if it has the intent to
improve the health of the subject and consists of the use of ac-
cepted practices. 30 Many BD prisoners are so situated because
accepted practices do not help them with their illness. This situa-
tion makes it impossible to meet both of these conditions.
Therefore, experimentation on most BD prisoners is illegal.
Many individuals with BD who are in prison are typically there
because they do not respond to traditional treatment, and instead
self-medicate through the use of drugs and alcohol. 13' These are
the individuals who need help the most. They need progress in the
treatment of this disease. Some even die because of the prison sys-
tem's inability to administer proper treatment.'12 In many states, all
125. See generally ALLEN M. HORNBLUM, AcREs OF SKIN; HUMAN EXPERIMENTS AT
HOLMESBURG PRISON 76-115 (1999).
126. Id. at 112-13.
127. Id. at 82-83 (describing malaria experiments at Statesville prison where "test par-
ticipants were 'all sure that some means would be found to give [them] consideration,' "
resulting in the "commutations of sentence or paroles to 317 of the 432 convicts who par-
ticipated in the malaria tests including 24 murderers and 1 rapist").
128. Id. at 113-14.
129. 45 C.ER. § 46.306 (2006).
130. 46 C.F.R. § 46.306(2) (2006).
131. See, e.g., Patrick Orr, Experts Give Testimony in Scalping Case, IDAHO STATESMAN, Sept.
10, 2005, at 1 (telling of a BD woman on trial for scalping). Sometimes BD patients who are
on medication commit crime during prescription-drug induced mania. See, e.g., John Alan
Cohan, Psychiatric Ethics and Emerging Issues of Psychopharmacology in the Treatment of Depression,
20J. CONTEMP. HEALTH L. & POL'Y 115, 146-47 (2003) (discussing the "Prozac Defense" in
criminal law).
132. See, e.g., Rick Brundrett, Richland Inmate's Widow Sues Jail's Mental Health Provider
Blamed for Suicide, THE STATE (Columbia S.C.), Aug. 31, 2005, at BI (telling of an inmate
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medications are cut off immediately upon incarceration to allow
the prison's health services department an opportunity to evaluate
the prisoner.133 Once prison doctors re-diagnose the prisoner as
having BD (which can take days, weeks, or more), an inmate can
begin his or her medicine again.3 It does not help matters that
these medications are often rather expensive for the prisons, giving
doctors an incentive to deny the diagnosis.35 Even BD prisoners
who receive medication may have inconsistent access to prescrip-
tions and/or therapy.
3 6
BD-induced suicide is all too present in correctional facilities 7
Amending the C.F.R. to allow consenting prisoners to participate
in BD research would increase the quantity of possible subjects for
experimentation. It would also increase the quality of subjects be-
cause many prisoners are patients for whom traditional treatment
has not been effective. BD inmates represent BD at its most de-
structive. If something is to be done, it must be done to help these
people. Who better to help than the prisoners themselves?
B. Implementation of a Rolling Consent Requirement
Human participation in research experimentation is subject to
the informed consent requirements of the C.F.R."8 Regulations
require the investigator to obtain the "legally effective informed
consent of the subject or the subject's legally authorized represen-
tative."""9 The basic elements of informed consent require that the
investigator explain to the subject a number of items, including
any possible benefits of the experiment, any foreseeable risks, con-
fidentiality concerns, and more.140
For BD research subjects, the informed consent requirements
outlined in the C.F.R. are not enough to solicit actual consent.
who "was found hanging in his cell .... In a letter to his wife the day before, [the inmate]
complained he had not received his medications for seven days").
133. See, e.g., Mary McLachlin & John Pacenti, Bipolar Inmate Rediagnosed, Denied Medi-
cine, PALM BEACH POST, Apr. 5, 2004, at lA.
134. Id.
135. Id.
136. See Kate Coscarelli, Former Inmates to Tell Hearing About Horrors Behind Bars: National
Panel Holding Newark Session on Corrections Problems, THE STAR-LEDGER (Newark, N.J.), July 19,
2005, at 13.
137. Brundrett, supranote 132.
138. Seegenerally34 C.F.R. § 97.116 (2006).
139. Id.
140. Id. at § 97.116(a).
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During a period of depression or during a manic episode, indi-
viduals with BD may be more inclined to agree to things that they
would not normally agree. A depressed patient may consent to an
incredibly risky experiment in an attempt to facilitate suicide. A
manic person, soaring on feelings of invincibility, may engage in a
similar experiment believing that she can "beat the odds" of possi-
ble harm. For this reason, a rolling consent system should be
implemented when BD individuals are serving as test subjects in
experiments with therapeutic, non-therapeutic, and mixed ele-
ments.
There is no way to ensure that a consenting BD subject is ever
really outside of mania and depression, but by requiring a series of
informed consent solicitations, the risk of "false positive" consents
will be greatly diminished. Investigators should be required to ob-
tain written consent from the BD subject three times, each time at
least forty-eight hours apart from each other, before beginning any
experimentation. Then, once experimentation has begun, signed
affirmative informed consent to continue the experiment must
again be obtained weekly from each subject.4 1 This procedure will
reduce the risk that the subject is simply agreeing to the experi-
ment in a manic or depressive state, or similarly, neglecting to
withdraw though he or she may wish to withdraw from participa-
tion.
Many BD patients have difficulty committing, whether it be to
relationships, jobs, or medical treatments.'42 If rolling consent is
given, then there is an increased possibility that the consenting BD
individual truly is committed to the experiment and will be more
likely to continue with the program. This procedure, in turn, will
hopefully result in fewer subjects dropping out of experiments be-
fore completion. With more subjects "sticking it out," investigators
will have more findings with which to proceed for further research.
With fewer subjects dropping out of experiments, results will be
more complete.
141. Id. at § 97.116(a)(8) (requiring that investigators provide a subject with a state-
ment that the subject "may discontinue participation at any time without penalty or loss of
benefits to which the subject is otherwise entitled."). This requirement is not enough for BD
patients. They must be informed of this right each week, and affirmative consent must be
obtained rather than relying on an omission of an expressed desire to withdraw from ex-
perimentation.
142. See, e.g., TORREY & KNABLE, supra note 38, at 240 (describing reasons for medica-
tion noncompliance).
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V. CONCLUSIONS
BD is a destructive disease capable of crippling those inflicted
with it as well as devastating society. Current research is progressing
very slowly. To facilitate the search for effective treatment, the
C.F.R. should be modified to allow consenting prisoners to serve as
research subjects. Additionally, to both yield more complete results
and to protect BD individuals from giving "false positive" informed
consent, a system of rolling consent should be implemented for all
research involving BD subjects. Something must be done to help
those with BD. With these suggested reforms, there is hope that
something can be done.
